Listed

4D Molecular Therapeutics, Inc.

FDMTNasdaqCIK 1650648HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$3.8m, Q2 FY2026
Operating income−$77.0m, Q2 FY2026
Net income−$72.9m, Q2 FY2026
4D Molecular Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m20.2Revenue, Q3 FY2023, three months to 2023-09-30$20.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-13, accession 0000950170-24-126370.Report this figure(0.0)Revenue, Q4 FY2023, three months to 2023-12-31−$19.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-28, accession 0000950170-25-030056. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2024, three months to 2024-03-31$28.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0000950170-25-067040.Report this figure0.0Revenue, Q2 FY2024, three months to 2024-06-30$5.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-11, accession 0000950170-25-106244.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$3.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$1.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-18, accession 0001193125-26-114075. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2025, three months to 2025-03-31$14.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$15.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure0.1Revenue, Q3 FY2025, three months to 2025-09-30$90.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure85.1Revenue, Q4 FY2025, three months to 2025-12-31$85.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-18, accession 0001193125-26-114075. Derived: 12-month figure less the 9-month figure.Report this figure3.0Revenue, Q1 FY2026, three months to 2026-03-31$3.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure3.8Revenue, Q2 FY2026, three months to 2026-06-30$3.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure
Research and development$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Operating income$m(14.0)Operating income, Q3 FY2023, three months to 2023-09-30−$14.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0000950170-24-126370.Report this figure(36.7)Operating income, Q4 FY2023, three months to 2023-12-31−$36.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-28, accession 0000950170-25-030056. Derived: 12-month figure less the 9-month figure.Report this figure(38.1)Operating income, Q1 FY2024, three months to 2024-03-31−$38.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0000950170-25-067040.Report this figure(42.5)Operating income, Q2 FY2024, three months to 2024-06-30−$42.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-11, accession 0000950170-25-106244.Report this figure(51.1)Operating income, Q3 FY2024, three months to 2024-09-30−$51.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure(56.1)Operating income, Q4 FY2024, three months to 2024-12-31−$56.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001193125-26-114075. Derived: 12-month figure less the 9-month figure.Report this figure(53.6)Operating income, Q1 FY2025, three months to 2025-03-31−$53.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure(59.5)Operating income, Q2 FY2025, three months to 2025-06-30−$59.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure(61.2)Operating income, Q3 FY2025, three months to 2025-09-30−$61.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure14.7Operating income, Q4 FY2025, three months to 2025-12-31$14.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-18, accession 0001193125-26-114075. Derived: 12-month figure less the 9-month figure.Report this figure(73.6)Operating income, Q1 FY2026, three months to 2026-03-31−$73.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure(77.0)Operating income, Q2 FY2026, three months to 2026-06-30−$77.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-13, accession 0000950170-24-126370.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-02-28, accession 0000950170-25-030056. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-08, accession 0000950170-25-067040.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-11, accession 0000950170-25-106244.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-18, accession 0001193125-26-114075. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure0.0Income tax, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure0.0Income tax, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure0.0Income tax, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-03-18, accession 0001193125-26-114075. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure0.0Income tax, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure
Net income$m(10.3)Net income, Q3 FY2023, three months to 2023-09-30−$10.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0000950170-24-126370.Report this figure(32.3)Net income, Q4 FY2023, three months to 2023-12-31−$32.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-28, accession 0000950170-25-030056. Derived: 12-month figure less the 9-month figure.Report this figure(32.4)Net income, Q1 FY2024, three months to 2024-03-31−$32.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure(35.0)Net income, Q2 FY2024, three months to 2024-06-30−$35.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure(43.8)Net income, Q3 FY2024, three months to 2024-09-30−$43.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure(49.7)Net income, Q4 FY2024, three months to 2024-12-31−$49.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001193125-26-114075. Derived: 12-month figure less the 9-month figure.Report this figure(48.0)Net income, Q1 FY2025, three months to 2025-03-31−$48.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure(54.7)Net income, Q2 FY2025, three months to 2025-06-30−$54.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure(56.9)Net income, Q3 FY2025, three months to 2025-09-30−$56.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure19.4Net income, Q4 FY2025, three months to 2025-12-31$19.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-18, accession 0001193125-26-114075. Derived: 12-month figure less the 9-month figure.Report this figure(68.8)Net income, Q1 FY2026, three months to 2026-03-31−$68.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure(72.9)Net income, Q2 FY2026, three months to 2026-06-30−$72.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure
Diluted EPS$ per share(0.24)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0000950170-24-126370.Report this figurenot reported(0.66)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.66 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0000950170-25-067040.Report this figure(0.63)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.63 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0000950170-25-106244.Report this figure(0.79)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.79 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figurenot reported(0.86)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.86 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure(0.98)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure(1.01)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$1.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figurenot reported(1.01)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure(1.04)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure
Basic EPS$ per share(0.24)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.24 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0000950170-24-126370.Report this figurenot reported(0.66)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.66 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0000950170-25-067040.Report this figure(0.63)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.63 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0000950170-25-106244.Report this figure(0.79)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.79 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figurenot reported(0.86)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.86 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure(0.98)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.98 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure(1.01)Basic EPS, Q3 FY2025, three months to 2025-09-30−$1.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figurenot reported(1.01)Basic EPS, Q1 FY2026, three months to 2026-03-31−$1.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure(1.04)Basic EPS, Q2 FY2026, three months to 2026-06-30−$1.04 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure

Balance sheet

Cash and equivalents$70.4m, Q2 FY2026
Long-term debt$19.6m, Q2 FY2026
Shareholders' equity$407.7m, Q2 FY2026
4D Molecular Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m276Cash and equivalents, Q3 FY2023, at 2023-09-30$275.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0000950170-23-062103.Report this figure249Cash and equivalents, FY2023, at 2023-12-31$249.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-28, accession 0000950170-25-030056.Report this figure276Cash and equivalents, Q1 FY2024, at 2024-03-31$275.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-05-09, accession 0000950170-24-056933.Report this figure189Cash and equivalents, Q2 FY2024, at 2024-06-30$189.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0000950170-24-094010.Report this figure188Cash and equivalents, Q3 FY2024, at 2024-09-30$187.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-13, accession 0000950170-24-126370.Report this figure149Cash and equivalents, FY2024, at 2024-12-31$149.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-18, accession 0001193125-26-114075.Report this figure134Cash and equivalents, Q1 FY2025, at 2025-03-31$133.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0000950170-25-067040.Report this figure77.2Cash and equivalents, Q2 FY2025, at 2025-06-30$77.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0000950170-25-106244.Report this figure48.6Cash and equivalents, Q3 FY2025, at 2025-09-30$48.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure60.2Cash and equivalents, FY2025, at 2025-12-31$60.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure72.5Cash and equivalents, Q1 FY2026, at 2026-03-31$72.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure70.4Cash and equivalents, Q2 FY2026, at 2026-06-30$70.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure
Current assets$m328Current assets, Q3 FY2023, at 2023-09-30$328.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0000950170-23-062103.Report this figure297Current assets, FY2023, at 2023-12-31$296.6m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-28, accession 0000950170-25-030056.Report this figure536Current assets, Q1 FY2024, at 2024-03-31$535.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-056933.Report this figure553Current assets, Q2 FY2024, at 2024-06-30$552.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-094010.Report this figure511Current assets, Q3 FY2024, at 2024-09-30$510.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0000950170-24-126370.Report this figure435Current assets, FY2024, at 2024-12-31$434.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-18, accession 0001193125-26-114075.Report this figure333Current assets, Q1 FY2025, at 2025-03-31$332.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0000950170-25-067040.Report this figure303Current assets, Q2 FY2025, at 2025-06-30$303.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0000950170-25-106244.Report this figure312Current assets, Q3 FY2025, at 2025-09-30$312.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure413Current assets, FY2025, at 2025-12-31$413.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure405Current assets, Q1 FY2026, at 2026-03-31$405.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure383Current assets, Q2 FY2026, at 2026-06-30$383.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure
Total assets$m362Total assets, Q3 FY2023, at 2023-09-30$361.6m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0000950170-23-062103.Report this figure340Total assets, FY2023, at 2023-12-31$339.9m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-28, accession 0000950170-25-030056.Report this figure630Total assets, Q1 FY2024, at 2024-03-31$629.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0000950170-24-056933.Report this figure620Total assets, Q2 FY2024, at 2024-06-30$620.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0000950170-24-094010.Report this figure604Total assets, Q3 FY2024, at 2024-09-30$604.0m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0000950170-24-126370.Report this figure560Total assets, FY2024, at 2024-12-31$560.4m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-18, accession 0001193125-26-114075.Report this figure516Total assets, Q1 FY2025, at 2025-03-31$515.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0000950170-25-067040.Report this figure474Total assets, Q2 FY2025, at 2025-06-30$473.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0000950170-25-106244.Report this figure424Total assets, Q3 FY2025, at 2025-09-30$424.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure567Total assets, FY2025, at 2025-12-31$566.7m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure513Total assets, Q1 FY2026, at 2026-03-31$512.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure493Total assets, Q2 FY2026, at 2026-06-30$492.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure
Current liabilities$m18.2Current liabilities, Q3 FY2023, at 2023-09-30$18.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0000950170-23-062103.Report this figure19.0Current liabilities, FY2023, at 2023-12-31$19.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-28, accession 0000950170-25-030056.Report this figure16.4Current liabilities, Q1 FY2024, at 2024-03-31$16.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-056933.Report this figure19.4Current liabilities, Q2 FY2024, at 2024-06-30$19.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-094010.Report this figure29.5Current liabilities, Q3 FY2024, at 2024-09-30$29.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0000950170-24-126370.Report this figure29.1Current liabilities, FY2024, at 2024-12-31$29.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-18, accession 0001193125-26-114075.Report this figure26.9Current liabilities, Q1 FY2025, at 2025-03-31$26.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0000950170-25-067040.Report this figure34.7Current liabilities, Q2 FY2025, at 2025-06-30$34.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0000950170-25-106244.Report this figure37.1Current liabilities, Q3 FY2025, at 2025-09-30$37.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure44.0Current liabilities, FY2025, at 2025-12-31$44.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure43.4Current liabilities, Q1 FY2026, at 2026-03-31$43.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure47.7Current liabilities, Q2 FY2026, at 2026-06-30$47.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure
Total liabilities$m31.7Total liabilities, Q3 FY2023, at 2023-09-30$31.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0000950170-23-062103.Report this figure32.1Total liabilities, FY2023, at 2023-12-31$32.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-28, accession 0000950170-25-030056.Report this figure29.3Total liabilities, Q1 FY2024, at 2024-03-31$29.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0000950170-24-056933.Report this figure31.8Total liabilities, Q2 FY2024, at 2024-06-30$31.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0000950170-24-094010.Report this figure51.1Total liabilities, Q3 FY2024, at 2024-09-30$51.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0000950170-24-126370.Report this figure49.8Total liabilities, FY2024, at 2024-12-31$49.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-18, accession 0001193125-26-114075.Report this figure46.0Total liabilities, Q1 FY2025, at 2025-03-31$46.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0000950170-25-067040.Report this figure52.7Total liabilities, Q2 FY2025, at 2025-06-30$52.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0000950170-25-106244.Report this figure55.0Total liabilities, Q3 FY2025, at 2025-09-30$55.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure61.0Total liabilities, FY2025, at 2025-12-31$61.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure61.1Total liabilities, Q1 FY2026, at 2026-03-31$61.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure85.0Total liabilities, Q2 FY2026, at 2026-06-30$85.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported0.0Long-term debt, FY2025, at 2025-12-31$0. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figurenot reported19.6Long-term debt, Q2 FY2026, at 2026-06-30$19.6m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure
Shareholders' equity$m330Shareholders' equity, Q3 FY2023, at 2023-09-30$329.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0000950170-24-126370.Report this figure308Shareholders' equity, FY2023, at 2023-12-31$307.8m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-18, accession 0001193125-26-114075.Report this figure601Shareholders' equity, Q1 FY2024, at 2024-03-31$600.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure588Shareholders' equity, Q2 FY2024, at 2024-06-30$588.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure553Shareholders' equity, Q3 FY2024, at 2024-09-30$552.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure511Shareholders' equity, FY2024, at 2024-12-31$510.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure470Shareholders' equity, Q1 FY2025, at 2025-03-31$469.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure421Shareholders' equity, Q2 FY2025, at 2025-06-30$420.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure369Shareholders' equity, Q3 FY2025, at 2025-09-30$369.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure506Shareholders' equity, FY2025, at 2025-12-31$505.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure452Shareholders' equity, Q1 FY2026, at 2026-03-31$451.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure408Shareholders' equity, Q2 FY2026, at 2026-06-30$407.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure

Cash flow

Operating cash flow−$70.0m, Q2 FY2026
Capital expenditure−$70.0k, Q4 FY2025
4D Molecular Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(1.2)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$1.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0000950170-24-126370. Derived: 9-month figure less the 6-month figure.Report this figure(24.7)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$24.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-28, accession 0000950170-25-030056. Derived: 12-month figure less the 9-month figure.Report this figure(29.1)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$29.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0000950170-25-067040.Report this figure(30.2)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$30.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0000950170-25-106244. Derived: 6-month figure less the 3-month figure.Report this figure(29.4)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$29.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001193125-25-273343. Derived: 9-month figure less the 6-month figure.Report this figure(45.9)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$45.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001193125-26-114075. Derived: 12-month figure less the 9-month figure.Report this figure(47.8)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$47.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure(43.4)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$43.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001193125-26-349173. Derived: 6-month figure less the 3-month figure.Report this figure(46.5)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$46.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001193125-25-273343. Derived: 9-month figure less the 6-month figure.Report this figure28.6Operating cash flow, Q4 FY2025, three months to 2025-12-31$28.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-18, accession 0001193125-26-114075. Derived: 12-month figure less the 9-month figure.Report this figure(68.1)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$68.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure(70.0)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$70.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-13, accession 0001193125-26-349173. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.4Capital expenditure, Q3 FY2023, three months to 2023-09-30$405.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-13, accession 0000950170-24-126370. Derived: 9-month figure less the 6-month figure.Report this figure0.5Capital expenditure, Q4 FY2023, three months to 2023-12-31$549.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-28, accession 0000950170-25-030056. Derived: 12-month figure less the 9-month figure.Report this figure0.7Capital expenditure, Q1 FY2024, three months to 2024-03-31$710.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0000950170-25-067040.Report this figure0.3Capital expenditure, Q2 FY2024, three months to 2024-06-30$349.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-11, accession 0000950170-25-106244. Derived: 6-month figure less the 3-month figure.Report this figure1.8Capital expenditure, Q3 FY2024, three months to 2024-09-30$1.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001193125-25-273343. Derived: 9-month figure less the 6-month figure.Report this figure0.9Capital expenditure, Q4 FY2024, three months to 2024-12-31$949.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-18, accession 0001193125-26-114075. Derived: 12-month figure less the 9-month figure.Report this figure0.6Capital expenditure, Q1 FY2025, three months to 2025-03-31$631.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0000950170-25-067040.Report this figure0.1Capital expenditure, Q2 FY2025, three months to 2025-06-30$66.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-13, accession 0001193125-26-349173. Derived: 6-month figure less the 3-month figure.Report this figure(0.1)Capital expenditure, Q3 FY2025, three months to 2025-09-30−$91.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001193125-25-273343. Derived: 9-month figure less the 6-month figure.Report this figure(0.1)Capital expenditure, Q4 FY2025, three months to 2025-12-31−$70.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-18, accession 0001193125-26-114075. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)70.27m, Q2 FY2026
4D Molecular Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares32.4Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3032,385,791 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0000950170-23-062103.Report this figure32.7Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3132,723,530 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0000950170-24-056933.Report this figure38.3Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3038,335,219 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0000950170-24-094010.Report this figure42.3Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3042,256,629 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0000950170-24-126370.Report this figure49.3Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3149,271,984 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0000950170-25-067040.Report this figure55.3Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3055,282,754 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0000950170-25-106244.Report this figure55.6Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3055,554,476 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure55.7Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3155,744,047 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure55.9Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3055,927,091 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure56.1Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3056,126,330 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-10, accession 0001193125-25-273343.Report this figure68.1Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3168,064,586 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001193125-26-211939.Report this figure70.3Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3070,272,018 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-13, accession 0001193125-26-349173.Report this figure

Shares outstanding: 49.78mShares outstanding, period not labelled, at 2024-02-2349,778,127 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-K filed 2024-02-29, accession 0000950170-24-023183.Report this figure at Feb 23, 2024, from the cover of the 10-K filed Feb 29, 2024.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.